Holen Sie sich die Stockscreener-App
2.08
0.95%
-0.02
Handel nachbörslich:
2.13
0.05
+2.40%
Schlusskurs vom Vortag:
$2.10
Offen:
$2.1494
24-Stunden-Volumen:
28,120
Relative Volume:
0.34
Marktkapitalisierung:
$35.02M
Einnahmen:
$709.00K
Nettoeinkommen (Verlust:
$-43.14M
KGV:
-0.4581
EPS:
-4.54
Netto-Cashflow:
$-20.35M
1W Leistung:
-5.88%
1M Leistung:
-5.88%
6M Leistung:
-36.97%
1J Leistung:
-39.71%
1-Tages-Spanne:
$2.08
$2.15
1-Wochen-Bereich:
$2.05
$2.3073
52-Wochen-Spanne:
$1.97
$3.49
OncoCyte Corporation Stock (OCX) Company Profile
Firmenname
OncoCyte Corporation
Sektor
Branche
Telefon
510-775-0515
Adresse
1010 Atlantic Avenue, Suite 102, Alameda, CA
Vergleichen Sie OCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.08 | 35.02M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
OncoCyte Corporation Aktie (OCX) Neueste Nachrichten
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock - Investing.com India
Oncocyte corp shareholder Patrick W Smith acquires $34,114 in stock By Investing.com - Investing.com Australia
OncoCyte (STU:7OC0) PS Ratio : 47.04 (As of Jan. 15, 2025) - GuruFocus.com
OncoCyte Co. (NASDAQ:OCX) Shares Bought by Geode Capital Management LLC - Defense World
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte Corporation (NASDAQ: OCX) Enters Amendment to Lease Agreement with Induce Biologics USA, Inc. and Cushing Ventures, LLCOn January 2, 2025, Oncocyte Corporation announced in a Form 8-K filing that it has entered into an Amendment to a - Defense World
Oncocyte Corp amends lease agreement, sets expiration date By Investing.com - Investing.com Nigeria
Oncocyte Corp amends lease agreement, sets expiration date - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - Markets Insider
Oncocyte names Dr. Paul Billings as Consulting CMO - Investing.com India
Oncocyte Taps Harvard-Trained Diagnostics Veteran Dr. Paul Billings as Chief Medical Officer - StockTitan
Medicare expands coverage for kidney transplant test By Investing.com - Investing.com Australia
OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com - Defense World
Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - The Manila Times
Oncocyte's VitaGraft Kidney Test Gains Expanded Medicare Coverage for Early Rejection Detection - StockTitan
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
Oncocyte corp investor Patrick Smith buys $192,166 in stock By Investing.com - Investing.com Nigeria
OncoCyte stock hits 52-week low at $1.97 amid market challenges - Investing.com Nigeria
Oncocyte corp director Arno Andrew buys $26,350 in shares - Investing.com India
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX) - Defense World
OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com - Defense World
Oncocyte to Participate in 'J.P. Morgan Week” and Host Investor Meetings - The Manila Times
Oncocyte corp CFO James Andrea acquires $45,800 in stock - Investing.com India
Oncocyte corp CFO James Andrea acquires $45,800 in stock By Investing.com - Investing.com Canada
Oncocyte Corp to Meet Investors at J.P. Morgan Healthcare Conference 2025 - StockTitan
OCXOncocyte Corporation Latest Stock News & Market Updates - StockTitan
OncoCyte stock hits 52-week low at $1.98 amid market challenges - Investing.com Nigeria
OncoCyte stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Oncocyte study shows potential for non-invasive brain tumor diagnosis By Investing.com - Investing.com Nigeria
Oncocyte study shows potential for non-invasive brain tumor diagnosis - Investing.com
OncoCyte announces publication of DetermaCNI assay data - TipRanks
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study - The Manila Times
Oncocyte's Brain Cancer Liquid Biopsy Test Shows Breakthrough 83% Detection Rate in Clinical Study - StockTitan
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms - The Manila Times
OncoCyte (LTS:0KCC) Shares Outstanding (EOP) : 13.37 Mil (As of Sep. 2024) - GuruFocus.com
OncoCyte announces VitaGraft data published in journal - TipRanks
Oncocyte's VitaGraft Kidney Test Detects Transplant Rejection 11 Months Earlier in Clinical Study - StockTitan
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
OCX (OncoCyte) EPS without NRI : $-2.33 (TTM As of Sep. 2024) - GuruFocus.com
OncoCyte stock plunges to 52-week low at $2.18 amid market challenges By Investing.com - Investing.com South Africa
OncoCyte stock plunges to 52-week low at $2.18 amid market challenges - Investing.com Nigeria
Finanzdaten der OncoCyte Corporation-Aktie (OCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):